Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer



Status:Completed
Conditions:Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Colorectal Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/14/2016
Start Date:December 1998
End Date:April 2004

Use our guide to learn which trials are right for you!

Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer

RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors,
decreasing the risk of metastatic cancer, preventing the formation of blood clots, and
improving quality of life in treating patients with advanced cancer that has not responded
to previous treatment. It is not yet known if standard therapy is more effective with or
without dalteparin in treating advanced breast, lung, colorectal, and prostate cancer.

PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of standard
therapy with or without dalteparin in treating patients who have advanced breast, lung,
colorectal, or prostate cancer that has not responded to previous chemotherapy or hormone
therapy.

OBJECTIVES: I. Compare the effect of low molecular weight heparin (dalteparin) plus standard
therapy versus standard therapy alone on the overall survival rate of patients with advanced
cancers. II. Compare the toxic effects of these regimens and the effect on the quality of
life of these patients. III. Assess the incidence of symptomatic thrombotic events such as
deep venous thrombosis (DVT), pulmonary embolus (PE), and clotted catheters in these
patients.

OUTLINE: This is a randomized study. Patients are stratified according to prognostic index
(good vs bad vs unsure), current therapy (systemic vs radiation vs both vs none), age (50 or
under vs over 50), disease site (breast vs colon vs small cell lung vs nonsmall cell lung vs
prostate), history of prior thrombotic event over 1 year ago (yes vs no), and gender.
Patients are randomized to receive low molecular weight heparin (dalteparin) plus standard
therapy or standard therapy alone.

DISEASE CHARACTERISTICS: Histologically or cytologically proven breast, lung, colorectal,
or prostate cancer that has failed prior chemotherapy or hormone therapy No active CNS
metastases Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance
status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3500/mm3
Platelet count at least 150,000/mm3 Fibrinogen above lower limits of normal Hepatic:
Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3
times ULN Prothrombin time no greater than 1.5 times ULN Active partial thromboplastin
time no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Other:
No history of heparin associated thrombocytopenia At least 1 year since prior
thromboembolic phenomenon such as deep venous thrombosis, pulmonary embolus, or clotted
catheter No prior intolerance of unfractionated or low molecular weight heparin

PRIOR CONCURRENT THERAPY: No concurrent anticoagulation therapy No concurrent enrollment
on systemic or radiation therapy study (therapy off study allowed)
We found this trial at
20
sites
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bismarck, North Dakota 58501
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Cedar Rapids, Iowa 52403
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Danville, Pennsylvania 17822
?
mi
from
Danville, PA
Click here to add this to my saved trials
300 East Locust St., Ste 350
Des Moines, Iowa 50309
(515) 244-7586
CCOP - Iowa Oncology Research Association The Iowa Oncology Research Association (IORA) was established by...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
400 E Third Street
Duluth, Minnesota 55805
(218) 786-3868
CCOP - Duluth The Duluth CCOP, established and funded by the National Cancer Institute (NCI)...
?
mi
from
Duluth, MN
Click here to add this to my saved trials
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Grand Forks, North Dakota 58201
?
mi
from
Grand Forks, ND
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
353 Fairmont Blvd
Rapid City, South Dakota 57701
(605) 719-1000
Rapid City Regional Hospital Regional Health is an integrated health care system of more than...
?
mi
from
Rapid City, SD
Click here to add this to my saved trials
Regina, Saskatchewan
?
mi
from
Regina,
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Cancer Center The Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Cloud, Minnesota 56303
?
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Scottsdale, Arizona 85259
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sioux City, Iowa 51101
?
mi
from
Sioux City, IA
Click here to add this to my saved trials
Sioux Falls, South Dakota 57104
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
?
mi
from
Toledo, OH
Click here to add this to my saved trials
509 W. University Avenue
Urbana, Illinois 61801
(217) 383-3516
CCOP - Carle Cancer Center The Carle Cancer Center Community Clinical Oncology Program (CCOP) in...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Wichita, Kansas 67214
?
mi
from
Wichita, KS
Click here to add this to my saved trials